Trials / Terminated
TerminatedNCT00375453
Dose Escalation Study of SH U04722 in Solid Tumors
Phase I, Open-label, Dose Escalation Study for Evaluation of Safety, Tolerability, Pharmacokinetics, and Tumor-suppressive Efficacy of SH U04722 in Patients With Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 20 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and tolerability of SH U04722 in patients with solid tumor cancers. In addition, this study will identify the recommended dose and administration schedule of SH U04722 for phase II development in Japanese cancer patients, evaluate the pharmacokinetic profile of SH U04722 and gather preliminary data on the effectiveness of SH U04722 in patients with solid tumors.
Detailed description
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SH U04722 |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2006-09-13
- Last updated
- 2014-12-31
Locations
3 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00375453. Inclusion in this directory is not an endorsement.